Announcements Trials
Browse Landscape

Phase

Phase 1 16Phase 2 12Phase 1/2 6Phase EARLY_PHASE1 1

Status

Terminated 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 23Metformin 14pembrolizumab 12Radiotherapy 12Biopsy 11Nivolumab 9Fluorouracil 9Cyclophosphamide 9Temozolomide 7Radiation 7Bevacizumab 7gallium 68 PSMA-11 6Sirolimus 6Rituximab 6Letrozole 6Etoposide 6Cisplatin 6Aspirin 6olaparib 5Surveys and Questionnaires 5Radiosurgery 5Oxaliplatin 5Irinotecan 5Indocyanine Green 5Granulocyte Colony-Stimulating Factor 5Fluorodeoxyglucose F18 5Dexamethasone 5aldesleukin 4Surgical Procedures, Operative 4Proflavine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Completed × entinostat × Clear all
NCT03018249 2021-11-16

Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer

National Cancer Institute (NCI)

Phase EARLY_PHASE1 Completed
50 enrolled 12 charts
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡